Phenotypes Associated with This Genotype

Genotype
MGI:6510806

• Allelic Composition: Rasa3^tm1.1Llp/Rasa3^tm1.1Llp; Tg(Mx1-cre)1Cgn/?
• Genetic Background: involves: 129S1/SvImJ * C57BL/6J * CBA/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

increased spleen weight ( J:301035 )

• resulting from stress erythropoiesis after Poly(I:C) treatment

abnormal erythropoiesis ( J:301035 )

• adults at 8-12 weeks of age were assessed after being injected with 300 ug Poly(I:C) every other day for 5 days and were found to have suppressed basal erythropoiesis with severe anemia, thrombocytopenia, and leukopenia, with very low CD45- erythroid and CD45+ non-erythroid cell counts in bone marrow, but progression between precursor stages is not affected, and stress erythropoiesis is found with markedly increased spleen size, increased red pulp, increased BFU-E and CFU-E, increased erythroblasts, and reticulocytosis

anemia ( J:301035 )

• profound anemia after Poly(I:C) treatment

decreased erythrocyte cell number ( J:301035 )

• after Poly(I:C) treatment

decreased hematocrit ( J:301035 )

• after Poly(I:C) treatment

decreased hemoglobin content ( J:301035 )

• after Poly(I:C) treatment

increased mean corpuscular volume ( J:301035 )

• after Poly(I:C) treatment

increased red blood cell distribution width ( J:301035 )

• after Poly(I:C) treatment

anisocytosis ( J:301035 )

• after Poly(I:C) treatment

poikilocytosis ( J:301035 )

• after Poly(I:C) treatment

thrombocytopenia ( J:301035 )

• after Poly(I:C) treatment

increased mean platelet volume ( J:301035 )

• after Poly(I:C) treatment

decreased leukocyte cell number ( J:301035 )

• after Poly(I:C) treatment

reticulocytosis ( J:301035 )

• after Poly(I:C) treatment

pancytopenia ( J:301035 )

• after Poly(I:C) treatment

increased megakaryocyte-erythroid progenitor cell number ( J:301035 )

• in spleen after Poly(I:C) treatment

hemolysis ( J:301035 )

• indicated by increased LDH and bilirubin after Poly(I:C) treatment

bone marrow failure ( J:301035 )

• after Poly(I:C) treatment

homeostasis/metabolism

increased circulating bilirubin level ( J:301035 )

• after Poly(I:C) treatment

increased circulating lactate dehydrogenase level ( J:301035 )

• after Poly(I:C) treatment

immune system

increased spleen weight ( J:301035 )

• resulting from stress erythropoiesis after Poly(I:C) treatment

decreased leukocyte cell number ( J:301035 )

• after Poly(I:C) treatment

bone marrow failure ( J:301035 )

• after Poly(I:C) treatment

growth/size/body

increased spleen weight ( J:301035 )

• resulting from stress erythropoiesis after Poly(I:C) treatment